CD19 and diffuse large B-cell lymphoma: Similarly, CD19-expressing RT-DLBCL cells (HPRT3, HPRT2, and HPRT1) derived from core biopsies of RT-DLBCL cases have been used to construct RT-PDX models via tail vein injection, enabling the preclinical evaluation of novel therapies [127].